Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teamwork: FDA And NIH Join Forces To Fund Neurodegenerative Disease Research, Medical Device Development Tools

Executive Summary

The two federal agencies are working together to research rare conditions and fund grants for small businesses creating medical device development tools.

You may also be interested in...



Collaboration Between Federal Agencies Seeks To Advance Cancer Treatments

The US FDA’s device center is teaming up with the National Cancer Institute to help small businesses that are developing innovative devices to treat cancer.

FDA FY 2024 Budget Includes 10% Funding Boost, But No Movement On Diagnostics

The FDA requested a 10% increase in budget authority for FY 2024, but diagnostic reform was left out of the proposal. 

Color Additive Risk Evaluation Tool Qualified As New Medical Device Development Tool

A color additive evaluation tool for polymeric medical devices was approved as an MDDT under the FDA’s voluntary program.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel